Tianda Pharmaceuticals Limited (0455) Fair Value & Analysis

Healthcare · HK · Market cap HK$185M

Below-average quality, and screening another 71% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (HK$0.0400). The favourable scenario is already priced in.
• Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts.
• A fairly wide model range (HK$0.0200 to HK$0.0400) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range HK$0.0850 – HK$0.4054 · fair‑value band HK$0.0200 – HK$0.0400 · the HK$0.1050 price screens above the HK$0.0300 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Tianda Pharmaceuticals Limited (0455) currently trades at HK$0.1050, while our model-based Fair Value estimate is HK$0.0300, implying the stock looks roughly 71.4% overvalued today. The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Over the trailing twelve months, Tianda Pharmaceuticals Limited generated revenue of HK$323M at a net margin of -21.7%. Revenue grew 7.2% year over year. It earns a return on equity of -14.6%. Net debt stands at HK$67.9M. Fundamentals as of Aug 13, 2026

Our scenario range runs from HK$0.0200 (bear case) to HK$0.0400 (bull case); at HK$0.1050, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 51% below its 52-week high and 30% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -71%, 0455 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Asset-Based (HK$0.1400) versus DCF Models (HK$0.0300). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Tianda Pharmaceuticals Limited, together with its subsidiaries, engages in the research and development, manufacture, and sale of pharmaceutical, biotechnology, and healthcare products in Mainland China, Hong Kong, and Australia. It operates through the Chinese Medicine; Pharmaceuticals and Medical Technologies; and Medical and Healthcare Services segments.

Full company description

Tianda Pharmaceuticals Limited, together with its subsidiaries, engages in the research and development, manufacture, and sale of pharmaceutical, biotechnology, and healthcare products in Mainland China, Hong Kong, and Australia. It operates through the Chinese Medicine; Pharmaceuticals and Medical Technologies; and Medical and Healthcare Services segments. The company offers Chinese herbal medicine, Chinese medicine decoction pieces, Chinese medicine products, and Chinese medicine clinical services. It also produces pharmaceutical products focusing on cardiovascular and cerebrovascular medication, respiratory infections, and pediatric diseases. In addition, the company trades agricultural by-products. The company was formerly known as Tianda Holdings Limited and changed its name to Tianda Pharmaceuticals Limited in September 2012. The company was incorporated in 1992 and is headquartered in Central, Hong Kong. Tianda Pharmaceuticals Limited is a subsidiary of Tianda Group Limited.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

Tianda Pharmaceuticals Limited reported revenue of HK$323M in FY2026 versus HK$510M in FY2022, a compound −10.8%/yr. Reported net income was −HK$70.0M in FY2026.

0455 screens 71% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →

Peer Group

Drug Manufacturers - Specialty & Generic · 624 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.